Naslov
Budget Impact Analysis of Pharmacist-Led Medication Management in Cardiovascular and Type 2 Diabetic Patients

Autori
Mucalo, Iva ; Brajković, Andrea ; Strgačić, Marija ; Ramalho-de-Oliveira, Djenane ; Ribaric, Elizabeta ; Bobinac, Ana

Izvornik
Healthcare (2227-9032) 10 (2022), 4; 722, 18

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
budget impact analysis ; comprehensive medication management services ; pharmacists’ services ; polypharmacy ; medication therapy management ; cardiovascular diseases ; type 2 diabetes mellitus

Sažetak
The paper aims to identify and measure the costs and savings associated with the delivery of Comprehensive Medication Management (CMM) services in Croatia in patients diagnosed with hypertension accompanied by at least one additional established cardiovascular disease (CVD) and/or type 2 diabetes mellitus (DMT2) who use five or more medicines daily. The budget impact analysis (BIA) employed in this study compares the total costs of CMM to the cost reductions expected from CMM. The cost reductions (or savings) are based on the reduced incidence of unwanted clinical events and healthcare service utilisation rates due to CMM. The BIA model is populated by data on medication therapy costs, labour, and training from the pilot CMM intervention introduced in Zagreb's main Health Centre, while relevant international published sources were used to estimate the utilisation, incidence, and unwanted clinical events rates. Total direct costs, including pharmacists' labour and training (EUR 2, 667, 098) and the increase in the cost of prescribed medication (EUR 5, 182, 864) amounted to EUR 7, 849, 962 for 3 years, rendering the cost per treated patient per year EUR 57. CMM is expected to reduce the utilisation rates of healthcare services and the incidence of unwanted clinical events, leading to a total 3-year reduction in healthcare costs of EUR 7, 787, 765. Given the total CMM costs of EUR 7, 849, 962, CMM's 3-year budget impact equals EUR 92, 869, rendering per treated patient an incremental cost of CMM EUR 0.67. Hence, CMM appears to be an affordable intervention for addressing medication mismanagement and irrational drug use.

Izvorni jezik
Engleski

Znanstvena područja
Farmacija, Ekonomija

POVEZANOST RADA